Prodrug
A prodrug is a medication or compound that does not work on its own. After intake, the body metabolizes it, which means the body changes it into a pharmacologically active drug. Doctors do not always give the active drug directly. Instead, a prodrug can change how the drug is taken in, spread through the body, broken down, and removed. Scientists call these steps ADME.
Prodrugs are often made to improve bioavailability, which is how much of a drug the body can actually use. This matters when a drug is not absorbed well from the gastrointestinal tract, the system that carries food through the stomach and intestines. A prodrug can also help a drug reach its intended target more often than other parts of the body. This can reduce unwanted effects. This is especially helpful in treatments like chemotherapy, which can cause serious side effects.
Prodrugs can also help medicines reach the brain. Most small drugs cannot pass through the blood brain barrier on their own. A prodrug can be designed to cross this barrier, and then the body changes it into the active drug.
The IUPAC defines a prodrug as a compound that changes inside the body before it has any effect. One way to think about prodrugs is as drugs that include special protective parts. These parts are used for a short time to change or remove unwanted properties of the original molecule.
History
Many herbal medicines contain glycosides. These are forms of a plant's active part that are linked to sugar. In the intestines, they break down and release the active part, the aglycone, which the body can absorb more easily. For example, salicin, a β-D-glucopyranoside, breaks down to release salicylic acid. Aspirin (acetylsalicylic acid) was first made by Felix Hoffmann at Bayer in 1897. It is a medicine made by people that turns into salicylic acid in the body. In other cases, such as codeine and morphine, the body changes the drug with enzymes in a process called activation. This forms sugar forms of the drug, called morphine-glucuronides, which can be stronger than the original.
The first synthetic medicine to fight germs, arsphenamine, was discovered in 1909 by Sahachiro Hata in the laboratory of Paul Ehrlich. It does not work against bacteria until the body changes it into an active form. In the same way, prontosil, the first sulfa drug, was discovered by Gerhard Domagk in 1932. The body must break it down to release the active molecule, sulfanilamide. Many other examples have been found since then. Terfenadine was the first non-sedating antihistamine, which is a medicine for allergies that does not make people very sleepy. It had to be taken off the market because it carried a small risk of a serious side effect. However, scientists found that terfenadine turns into the active molecule fexofenadine, which does not carry the same risk. So fexofenadine could be sold as a safer replacement. Loratadine is another non-sedating antihistamine. It turns into desloratadine in the body, and desloratadine is mostly responsible for the allergy-fighting effects. Because loratadine does not have terfenadine's side effects, both loratadine and its active metabolite, desloratadine, are still sold today.
Approved prodrugs
About 10% of all drugs sold around the world can be considered prodrugs. Since 2008, at least 30 prodrugs have been approved by the FDA. Seven prodrugs were approved in 2015, and six were approved in 2017.
Some prodrugs approved later include dabigatran etexilate (2010), gabapentin enacarbil (2011), sofosbuvir (2013), tedizolid phosphate (2014), isavuconazonium (2015), aripiprazole lauroxil (2015), selexipag (2015), latanoprostene bunod (2017), benzhydrocodone (2018), tozinameran (2020), serdexmethylphenidate (2021), and benzgalantamine (2024).
Classification
Prodrugs are sorted into two main types. The types depend on where the body changes them into the active drug. Type I prodrugs are changed inside the body's cells. Examples include anti-viral drugs called nucleoside analogs, which must be phosphorylated, and the cholesterol-lowering statins. Type II prodrugs are changed outside cells, mostly in digestive fluids or in the circulatory system, especially in the blood. Salicin is one example. Some enzyme prodrugs are also Type II. Doctors may use them in chemotherapy or immunotherapy.
Both main types can be divided into smaller groups. For Type I, the groups depend on whether the drug is changed in the same place inside the cell where it works. For Type II, the groups depend on whether the change happens in the digestive fluids or in the circulatory system.
| Type | Bioactivation site | Subtype | Tissue location of bioactivation | Examples |
|---|---|---|---|---|
| Type I | Intracellular | Type IA | Therapeutic target tissues/cells | Aciclovir, fluorouracil, cyclophosphamide, diethylstilbestrol diphosphate, L-DOPA, mercaptopurine, mitomycin, zidovudine, Hypoxia-activated prodrugs |
| Type IB | Metabolic tissues (liver, GI mucosal cell, lung etc.) | Carbamazepine, captopril, carisoprodol, heroin, molsidomine, leflunomide, paliperidone, phenacetin, primidone, psilocybin, sulindac, fursultiamine | ||
| Type II | Extracellular | Type IIA | GI fluids | Loperamide oxide, oxyphenisatin, sulfasalazine |
| Type IIB | Systemic circulation and other extracellular fluid compartments | Acetylsalicylate, bacampicillin, bambuterol, chloramphenicol succinate, dipivefrin, fosphenytoin, lisdexamfetamine, pralidoxime | ||
| Type IIC | Therapeutic target tissues/cells | ADEPTs, GDEPTs, VDEPTs |
Subtypes
Prodrugs are sorted into subtypes based on where they become active drugs in the body. Type IA includes many antimicrobial and chemotherapy medicines, such as 5-flurouracil. Type IB prodrugs need metabolic enzymes, especially in liver cells, to become active inside cells. Type II prodrugs become active outside cells. This can happen in the fluids of the gut (Type IIA), in the bloodstream and other body fluids (Type IIB), or near the target tissues or cells (Type IIC). They use common enzymes, such as esterases and phosphatases, or enzymes that target a specific place.
A prodrug can belong to more than one subtype. This is called Mixed-Type. If it becomes active in several places at the same time, it is written as "Type IA/IB," for example with HMG Co-A reductase inhibitors and some chemotherapy medicines. If it becomes active in steps, one after another, it is written with a dash, such as "Type IIA-IA." One example is tenofovir disoproxil. Many antibody-, virus-, and gene-directed enzyme prodrug therapies (ADEPTs, VDEPTs, GDEPTs) and some proposed nanoparticle- or nanocarrier-linked drugs can be Mixed-Type prodrugs that work in steps. A slash "/" shows steps that happen at the same time. A dash "-" shows steps that happen in order.

Quiz time!
4 questions about Prodrug
What is a prodrug?
Keep exploring
This article is a child-friendly adaptation of the Wikipedia article on Prodrug, available under CC BY-SA 4.0.